TheraRadar
← Back
Data updated: Jun 28, 2026

MATHESON TRI-GAS INC

Pharma
Pharmaceuticals

MATHESON TRI-GAS INC is a pharmaceutical company with 5 FDA-approved products.

2013
Since
5
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
5 Small Molecules

MATHESON TRI-GAS INC's Key Drugs

MATHESON TRI-GAS INC's core commercial portfolio centers on MEDICAL AIR, USP, HELIUM, USP, NITROGEN, NF — its most strategically important drugs approved in the last 15 years.

MEDICAL AIR, USP
Respiratory
Approved 2013
HELIUM, USP
Respiratory
Approved 2013
NITROGEN, NF
Other
Approved 2013
OXYGEN, USP
Respiratory
Approved 2013
NITROUS OXIDE, USP
Other
Approved 2013

MATHESON TRI-GAS INC's Recent FDA Approvals

MATHESON TRI-GAS INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MEDICAL AIR, USP NDA
2026-02-17
MEDICAL AIR, USP NDA
2024-07-13
medical air

MATHESON TRI-GAS INC's Therapeutic Areas

Disease areas where MATHESON TRI-GAS INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MATHESON TRI-GAS INC Pipeline Snapshot

Active clinical trials for MATHESON TRI-GAS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MEDICAL AIR, USP leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling